



### SENATE BILL No. 439

DIGEST OF SB 439 (Updated February 10, 2015 2:13 pm - DI 104)

Citations Affected: IC 12-15; IC 12-23.

Synopsis: Controlled substances. Limits Medicaid reimbursement for Subutex and Suboxone or an similar trade name or generic of the drug when the drug was prescribed for the treatment of pain management to only if the drug was prescribed by a physician who meets certain requirements. Allows for the office of Medicaid policy and planning to require prior authorization for these drugs when being prescribed for substance abuse treatment as determined by the board or when being prescribed for more than six months. Requires the division of mental health and addiction to adopt rules concerning: (1) opioid treatment by an opioid treatment provider; (2) take home opioid treatment medications; (3) clinical standards for tapering of a patient, relapse, and overdose prevention; and (4) specified standards and protocols for an opioid treatment provider. Requires an opioid treatment provider to periodically and randomly test a patient for specified drugs during treatment.

Effective: July 1, 2015.

## Hershman, Charbonneau, Stoops

January 20, 2015, read first time and referred to Committee on Health & Provider Services. February 5, 2015, amended, reported favorably — Do Pass. February 10, 2015, read second time, amended, ordered engrossed.



First Regular Session 119th General Assembly (2015)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2014 Regular Session and 2014 Second Regular Technical Session of the General Assembly.

# **SENATE BILL No. 439**

A BILL FOR AN ACT to amend the Indiana Code concerning human services.

Be it enacted by the General Assembly of the State of Indiana:

1	SECTION 1. IC 12-15-35-35 IS AMENDED TO READ AS
2	FOLLOWS [EFFECTIVE JULY 1, 2015]: Sec. 35. (a) Except as
3	provided in IC 12-15-35.5-9, before the board develops a program to
4	place a single source drug on prior approval, restrict the drug in its use,
5	or establish a drug monitoring process or program to measure or restrict
6	utilization of single source drugs other than in the SURS program, the
7	board must meet the following conditions:
8	(1) Make a determination, after considering evidence and credible
9	information provided to the board by the office and the public,
10	that placing a single source drug on prior approval or restricting
11	the drug's use will not:
12	(A) impede the quality of patient care in the Medicaid
13	program; or
14	(B) increase costs in other parts of the Medicaid program,
15	including hospital costs and physician costs.
16	(2) Meet to review a formulary or a restriction on a single source



1	drug after the office provides at least fifteen (15) days notification
2	to the public that the board will review the formulary or
3	restriction on a single source drug at a particular board meeting.
4	The notification shall contain the following information:
5	(A) A statement of the date, time, and place at which the board
6	meeting will be convened.
7	(B) A general description of the subject matter of the board
8	meeting.
9	(C) An explanation of how a copy of the formulary to be
10	discussed at the meeting may be obtained.
11	The board shall meet to review the formulary or the restriction on
12	a single source drug at least fifteen (15) days but not more than
13	sixty (60) days after the notification.
14	(3) Ensure that:
15	(A) there is access to at least two (2) alternative drugs within
16	each therapeutic classification, if available, on the formulary;
17	and
18	(B) a process is in place through which a Medicaid recipient
19	has access to medically necessary drugs.
20	(4) Reconsider the drug's removal from its restricted status or
21	from prior approval not later than six (6) months after the single
22	source drug is placed on prior approval or restricted in its use.
23	(5) Ensure that the program provides either telephone or FAX
24	approval or denial Monday through Friday, twenty-four (24) hours
25	a day. The office must provide the approval or denial within
26	twenty-four (24) hours after receipt of a prior approval request.
27	The program must provide for the dispensing of at least a
28	seventy-two (72) hour supply of the drug in an emergency
29	situation or on weekends.
30	(6) Ensure that any prior approval program or restriction on the
31	use of a single source drug is not applied to prevent acceptable
32	medical use for appropriate off-label indications.
33	(b) The board shall advise the office on the implementation of any
34	program to restrict the use of brand name multisource drugs.
35	(c) The board shall consider:
36	(1) health economic data;
37	(2) cost data; and
38	(3) the use of formularies in the non-Medicaid markets;
39	in developing its recommendations to the office.
40	SECTION 2. IC 12-15-35.5-9 IS ADDED TO THE INDIANA
41	CODE AS A <b>NEW</b> SECTION TO READ AS FOLLOWS
42	[EFFECTIVE JULY 1, 2015]: Sec. 9. (a) The office may not



trade name or generic of the drug if the drug was prescribed the treatment of pain or pain management, unless the prescril is a physician licensed under IC 25-22.5 who:  (1) has obtained a waiver from the federal Substance Abrand Mental Health Services Administration (SAMSHA) a meets the qualifying standards required to treat opin addicted patients in an office-based setting; and  (2) has a valid federal Drug Enforcement Administration identification number and a Drug Enforcement Administration in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantabuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standamedical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opic treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a		
the treatment of pain or pain management, unless the prescril is a physician licensed under IC 25-22.5 who:  (1) has obtained a waiver from the federal Substance Abi and Mental Health Services Administration (SAMSHA) a meets the qualifying standards required to treat opina addicted patients in an office-based setting; and  (2) has a valid federal Drug Enforcement Administratic identification number and a Drug Enforcement Administratic identification number that specifically authorizes treatment in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for the treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment prographroved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COID AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opit treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		reimburse under Medicaid for Subutex, Suboxone, or a similar
is a physician licensed under IC 25-22.5 who:  (1) has obtained a waiver from the federal Substance Aba and Mental Health Services Administration (SAMSHA) a meets the qualifying standards required to treat opin addicted patients in an office-based setting; and (2) has a valid federal Drug Enforcement Administration registration number and a Drug Enforcement Administration in an office-based setting. (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse: (1) Prior authorization may be required for a prescription drug described in subsection (a): (A) when the prescription drug is prescribed for more the six (6) months; or (B) as determined by the board. (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substantial abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment progra approved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COID AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECT JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standare medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opit treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		trade name or generic of the drug if the drug was prescribed for
(1) has obtained a waiver from the federal Substance Abiand Mental Health Services Administration (SAMSHA) a meets the qualifying standards required to treat oping addicted patients in an office-based setting; and (2) has a valid federal Drug Enforcement Administration in the interest of the prescription number and a Drug Enforcement Administration in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantiabuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment progress approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opit treatment by an opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		the treatment of pain or pain management, unless the prescriber
and Mental Health Services Administration (SAMSHA) a meets the qualifying standards required to treat opic addicted patients in an office-based setting; and (2) has a valid federal Drug Enforcement Administration registration number and a Drug Enforcement Administration identification number that specifically authorizes treatment in an office-based setting. (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a): (A) when the prescription drug is prescribed for more the six (6) months; or (B) as determined by the board. (2) The office may reimburse for the prescription drug; more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substant abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COM AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]; Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standar medical practices in opioid treatment for substance abuse, in division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		is a physician licensed under IC 25-22.5 who:
meets the qualifying standards required to treat opic addicted patients in an office-based setting; and  (2) has a valid federal Drug Enforcement Administration registration number and a Drug Enforcement Administration in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantiabuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTING JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standarmedical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opiot treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	5	(1) has obtained a waiver from the federal Substance Abuse
addicted patients in an office-based setting; and (2) has a valid federal Drug Enforcement Administration registration number and a Drug Enforcement Administration in an office-based setting. (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse: (1) Prior authorization may be required for a prescription drug described in subsection (a): (A) when the prescription drug is prescribed for more the six (6) months; or (B) as determined by the board. (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substantial abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment programproved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMMINICATION AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	6	and Mental Health Services Administration (SAMSHA) and
(2) has a valid federal Drug Enforcement Administrative registration number and a Drug Enforcement Administrative identification number that specifically authorizes treatment in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for a treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standare medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		meets the qualifying standards required to treat opioid
registration number and a Drug Enforcement Administratic identification number that specifically authorizes treatment in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for a treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more than six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standare medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	8	addicted patients in an office-based setting; and
identification number that specifically authorizes treatment in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for a treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment programa approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA CO. AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECT] JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standarmedical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	9	(2) has a valid federal Drug Enforcement Administration
in an office-based setting.  (b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment programa approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	10	registration number and a Drug Enforcement Administration
(b) The following apply to a prescription drug described subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment progration approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COINT AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTF JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		identification number that specifically authorizes treatment
subsection (a) for a Medicaid recipient if the prescription is for treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantial abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment progress approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COISTAN A NEW CHAPTER TO READ AS FOLLOWS [EFFECTF JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standare medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		in an office-based setting.
treatment of substance abuse:  (1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substance abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment progration approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMBAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	13	(b) The following apply to a prescription drug described in
(1) Prior authorization may be required for a prescription drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug amore than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substantabuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment programaproved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMMENTAGE ANEW CHAPTER TO READ AS FOLLOWS [EFFECTING JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standamedical practices in opioid treatment for substance abuse, addivision shall adopt rules under IC 4-22-2 concerning opiot treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		subsection (a) for a Medicaid recipient if the prescription is for the
drug described in subsection (a):  (A) when the prescription drug is prescribed for more the six (6) months; or  (B) as determined by the board.  (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substant abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment programaproved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMMENT AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTING JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers  Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opions treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	15	treatment of substance abuse:
(A) when the prescription drug is prescribed for more the six (6) months; or (B) as determined by the board. (2) The office may reimburse for the prescription drug is more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substant abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLORS AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVILY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standared medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		(1) Prior authorization may be required for a prescription
six (6) months; or (B) as determined by the board. (2) The office may reimburse for the prescription drug; more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substantabuse; and (B) the prescriber: (i) is treating as part of an opioid treatment prograpproved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMBAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standamedical practices in opioid treatment for substance abuse, division shall adopt rules under IC 4-22-2 concerning opions treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		drug described in subsection (a):
(B) as determined by the board. (2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substantabuse; and (B) the prescriber: (i) is treating as part of an opioid treatment programapproved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMMENTAGE AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE] JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standamedical practices in opioid treatment for substance abuse, addivision shall adopt rules under IC 4-22-2 concerning opions treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		(A) when the prescription drug is prescribed for more than
(2) The office may reimburse for the prescription drug more than six (6) months for a Medicaid recipient only if: (A) the drug is prescribed for the treatment of substant abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment prograsproved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLORS AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVELY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standare medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opion treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		six (6) months; or
more than six (6) months for a Medicaid recipient only if:  (A) the drug is prescribed for the treatment of substant abuse; and  (B) the prescriber:  (i) is treating as part of an opioid treatment prograte approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA CONTAINANA CONTAINANANA CONTAINANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANA CONTAINANANA CONTAINANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANANA CONTAINANA CONTAINANANA CONTAINANANA CONTAINANA		(B) as determined by the board.
(A) the drug is prescribed for the treatment of substantial abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment prograssing approved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19. SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMBAS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTT JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.	21	(2) The office may reimburse for the prescription drug for
abuse; and (B) the prescriber: (i) is treating as part of an opioid treatment progra approved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COINT AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVALY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		more than six (6) months for a Medicaid recipient only if:
(B) the prescriber:  (i) is treating as part of an opioid treatment progra approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMMENTARY AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTING JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	23	(A) the drug is prescribed for the treatment of substance
(i) is treating as part of an opioid treatment progra approved and certified under and meets requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COMMENTARY AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2015]:  Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		abuse; and
approved and certified under and meets requirements of IC 12-23-18; or  (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLORS (SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLORS (SEFFECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLORS (IN 12-23-19) IS ADDED	25	(B) the prescriber:
requirements of IC 12-23-18; or (ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA CORM AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standary medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.	26	(i) is treating as part of an opioid treatment program
(ii) meets the requirements of IC 12-23-19.  SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA CO. AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTI JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standa medical practices in opioid treatment for substance abuse, addivision shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		* *
SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA COLL AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE]  LULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standar medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		• · · · · · · · · · · · · · · · · · · ·
AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTI JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standa medical practices in opioid treatment for substance abuse, a division shall adopt rules under IC 4-22-2 concerning opio treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		•
JULY 1, 2015]: Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standa medical practices in opioid treatment for substance abuse, division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		SECTION 3. IC 12-23-19 IS ADDED TO THE INDIANA CODE
Chapter 19. Opioid Treatment Providers Sec. 1. Subject to federal law and consistent with standar medical practices in opioid treatment for substance abuse, addivision shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		AS A <b>NEW</b> CHAPTER TO READ AS FOLLOWS [EFFECTIVE
Sec. 1. Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, and division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.	32	JULY 1, 2015]:
medical practices in opioid treatment for substance abuse, a division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		Chapter 19. Opioid Treatment Providers
division shall adopt rules under IC 4-22-2 concerning opic treatment by an opioid treatment provider.  Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		Sec. 1. Subject to federal law and consistent with standard
treatment by an opioid treatment provider. Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		medical practices in opioid treatment for substance abuse, the
Sec. 2. (a) An opioid treatment provider shall periodically a randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider:  (1) Methadone.		division shall adopt rules under IC 4-22-2 concerning opioid
randomly test, including before receiving treatment, a patient the following during the patient's treatment by the provider: (1) Methadone.		• •
the following during the patient's treatment by the provider: (1) Methadone.		Sec. 2. (a) An opioid treatment provider shall periodically and
41 (1) Methadone.		randomly test, including before receiving treatment, a patient for
42 <b>(2)</b> Cocaine.		
	42	(2) Cocaine.



1	(3) Opiates.
2	(4) Amphetamines.
3	(5) Barbiturates.
4	(6) Tetrahydrocannabinol.
5	(7) Benzodiazepines.
6	(8) Any other suspected or known drug that may have been
7	abused by the patient.
8	(b) If a patient tests positive under a test described in subsection
9	(a) for:
10	(1) a controlled substance other than a drug for which the
11	patient has a prescription or that is part of the patient's
12	treatment plan with the provider; or
13	(2) an illegal drug other than the drug that is part of the
14	patient's treatment plan with the provider;
15	the opioid treatment provider and the patient shall review the
16	treatment plan and consider changes with the goal of opioic
17	abstinence.
18	Sec. 3. The division shall adopt rules under IC 4-22-2 to
19	establish the following:
20	(1) A requirement that an opioid treatment provider has
21	determined that the benefit to the patient in receiving the take
22	home opioid treatment medication outweighs the potentia
23	risk of diversion of the take home opioid treatment
24	medication.
25	(2) Clinical standards for:
26	(A) the appropriate tapering of a patient on and off ar
27	opioid treatment medication;
28	(B) relapse; and
29	(C) overdose prevention.
30	(3) Standards and protocols for an opioid treatment provide
31	to do the following:
32	(A) Assess new opioid treatment patients to determine the
33	most effective opioid treatment medications to start the
34	patient's opioid treatment.
35	(B) Ensure that each patient voluntarily chooses
36	maintenance treatment and that relevant facts concerning
37	the use of opioid treatment medications, including
38	nonaddictive medication options, are clearly and
39	adequately explained to the patient.
40	(C) Have appropriate opioid treatment patients who are
41	receiving methadone for opioid treatment move to
42	receiving other approved opioid treatment medications.



### COMMITTEE REPORT

Madam President: The Senate Committee on Health and Provider Services, to which was referred Senate Bill No. 439, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Page 3, line 1, delete "the following drugs" and insert "**Subutex**, **Suboxone**,".

Page 3, line 3, delete ":" and insert ", unless the prescriber is a physician licensed under IC 25-22.5 who:

- (1) has obtained a waiver from the federal Substance Abuse and Mental Health Services Administration (SAMSHA) and meets the qualifying standards required to treat opioid addicted patients in an office-based setting; and
- (2) has a valid federal Drug Enforcement Administration registration number and a Drug Enforcement Administration identification number that specifically authorizes treatment in an office-based setting."
- Page 3, delete lines 4 through 5.
- Page 3, line 9, delete "is not" and insert "may be".
- Page 3, line 9, delete "the initial" and insert "a prescription drug described in subsection (a):
  - (A) when the prescription drug is prescribed for more than six (6) months; or
  - (B) as determined by the board.".
  - Page 3, delete lines 10 through 19.
  - Page 3, line 20, delete "(3)" and insert "(2)".
  - Page 3, delete lines 30 through 42.
  - Page 4, delete lines 1 through 2.
- Page 4, line 7, delete "An opioid treatment provider shall not operate in" and insert "Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, the division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider."
  - Page 4, delete lines 8 through 40.
  - Page 4, line 41, delete "3." and insert "2.".
- Page 5, line 18, delete "comply with the" and insert "review the treatment plan and consider changes with the goal of opioid abstinence."
  - Page 5, delete lines 19 through 42.
  - Page 6, delete lines 1 through 16.



Page 6, line 17, delete "5. (a)" and insert "3.".

Page 6, line 19, delete "obtain" and insert "has determined that the benefit to the patient in receiving the take home opioid treatment medication outweighs the potential risk of diversion of the take home opioid treatment medication."

Page 6, delete lines 20 through 36.

Page 6, line 37, delete "(3)" and insert "(2)".

Page 6, line 37, after "for" insert ":

**(A)**".

Page 6, line 38, delete "." and insert ";

- (B) relapse; and
- (C) overdose prevention.".

Page 6, delete lines 39 through 41.

Page 6, line 42, delete "(5)" and insert "(3)".

Page 7, line 7, after "medications" insert ", including nonaddictive medication options,".

Page 7, delete lines 12 through 42.

Delete page 8.

and when so amended that said bill do pass.

(Reference is to SB 439 as introduced.)

MILLER PATRICIA, Chairperson

Committee Vote: Yeas 10, Nays 0.

### SENATE MOTION

Madam President: I move that Senate Bill 439 be amended to read as follows:

Page 3, line 1, delete "an equivalent" and insert "a similar trade name"

Page 3, line 25, delete "is either".

Page 3, line 26, after "(i)" insert "is".

Page 3, line 29, delete "certified under and".

Page 3, line 34, delete "Provider Certification" and insert "**Providers**".

(Reference is to SB 439 as printed February 6, 2015.)

**HERSHMAN** 

